Med-X is preparing for a possible NASDAQ listing (ticker: MXRX)

Med-X is preparing for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before global validation changes everything. In independent lab studies, Med-X's all-natural pesticides have outperformed chemical brands in certain use cases, delivering powerful results without the toxic tradeoffs associated with traditional pest control. Now, Med-X is pursuing a potential milestone that could redefine the industry: becoming the first botanical pesticide ever pre-qualified by the World Health Organization. The global biopesticide market is projected to grow nearly 3x by 2030, expanding from $5.8 billion to $17.6 billion as governments move away from synthetic chemicals. A WHO pre-qualification would position Nature-Cide as a globally recognized solution for public health, agriculture, and mosquito-borne disease control – opening doors that most pesticide companies can't access. Nature-Cide's plant-based formulation prioritizes safety while delivering industrial-grade performance, challenging long-held assumptions about what botanical solutions can achieve on a global scale. NASDAQ Ticker: MXRX Reserved! The Real Opportunity to Become a Shareholder Is Now! Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, agricultural, and public-health sectors. Proudly manufactured in the USA, Nature-Cide reflects a commitment to scalable, sustainable innovation. Already sold through eCommerce giants Amazon, Walmart, and Kroger, and expanding into 41 international markets, Med-X is positioning itself for its next major chapter. Simpler. Safer. More Effective Pesticides. Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold. Disclosures This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com